Addyi, the female Viagra

The pink pill, also known as Addyi or flibanserin, has often been referred to as "female Viagra." However, this nickname is misleading, as the two drugs work in completely different ways. Addyi is designed to target lost libido in pre-menopausal women by enhancing sexual desire and decreasing emotional distress.

Understanding the target group: premenopausal women and hypoactive sexual desire disorder (HSDD)

Addyi is intended for premenopausal women suffering from hypoactive sexual desire disorder (HSDD), a chronically low libido that causes extreme interpersonal strain and distress. This condition affects many women, and Addyi aims to provide a solution to improve their sexual health and well-being.

The science behind Addyi: how it enhances sexual desire and decreases emotional distress

Flibanserin has been studied in clinical trials involving over 11,000 women.

The results showed statistically significant effects over placebo on three key measurements: increases in sexual desire (measured by the female sexual function index), decreases in distress (measured by the female sexual distress scale), and increases in satisfying sexual events. Women who took flibanserin reported an average of 0.5 to 1.0 additional satisfying sexual events per month compared to those given a placebo.

Comparing Addyi (flibanserin) and Viagra (sildenafil): differences in function and effects

While Viagra (sildenafil) is known for its effect on men's sexual performance by improving blood flow to the penis and helping men get and maintain an erection, it does not affect arousal or libido. On the other hand, Addyi (flibanserin) does not improve sexual performance but focuses on enhancing sexual desire and decreasing emotional distress in premenopausal women.

U.S.

Food and Drug Administration (FDA) approval and its significance The FDA approved Addyi in August 2015, making it the first prescription drug to treat low sex drive in women. This approval marked a significant milestone for women's sexual health and paved the way for further research and development of treatments targeting female sexual dysfunctions.

The role of Sprout Pharmaceuticals in developing Addyi

Sprout Pharmaceuticals played a crucial role in the development of Addyi, the breakthrough medication for women's sexual health. Their dedication and research efforts brought this groundbreaking drug to the market, offering a solution for women suffering from HSDD.

Costs and insurance coverage for Addyi

Initially, Addyi was priced at $800 per month, making it difficult for many women to access the medication. However, the cost has since been reduced to $99 per month out of pocket, and it may be as low as $25 per month if insurance covers the treatment. This makes Addyi more accessible to a larger number of women who can benefit from its effects.

The importance of Addyi in the context of women's sexual health

Addyi represents a significant breakthrough in women's sexual health, addressing a previously unmet need for premenopausal women with HSDD. By enhancing sexual desire and decreasing emotional distress, Addyi improves the quality of life for countless women, fostering healthier relationships and a greater sense of well-being.